Literature DB >> 22289985

Leukemia risk models in primary myelofibrosis: an International Working Group study.

A Tefferi, A Pardanani, N Gangat, K H Begna, C A Hanson, D L Van Dyke, D Caramazza, A M Vannucchi, E Morra, M Cazzola, A Pereira, F Cervantes, F Passamonti.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22289985     DOI： 10.1038/leu.2011.374

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  21 in total

1.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

Authors:  P Guglielmelli; T L Lasho; G Rotunno; J Score; C Mannarelli; A Pancrazzi; F Biamonte; A Pardanani; K Zoi; A Reiter; A Duncombe; T Fanelli; D Pietra; E Rumi; C Finke; N Gangat; R P Ketterling; R A Knudson; C A Hanson; A Bosi; A Pereira; R Manfredini; F Cervantes; G Barosi; M Cazzola; N C P Cross; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2014-02-19       Impact factor: 11.528

2.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

Review 3.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

Review 4.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

5.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  Lucia Masarova; Ahmad Alhuraiji; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Jorge Cortes; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2018-01-17       Impact factor: 2.997

Review 6.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 7.  Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?

Authors:  Auro Viswabandya; Rebecca Devlin; Vikas Gupta
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

8.  Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Sherry Pierce; Jorge Cortes; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-02-04

9.  Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients.

Authors:  M C Souza; C A Rodrigues; M R R Silva; J Ribeiro; R Tognon; F A Castro; B P Simões; E X Souto; M L Chauffaille
Journal:  Med Oncol       Date:  2013-04-09       Impact factor: 3.064

10.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.